Lori Starr
Internal Medicine · Macon, GANPI 1598295719
Payments from drug & device makers
Across 449 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$594
- AbbVie$553
- Novo Nordisk$551
- Astellas Pharma US Inc$500
- Novartis$438
- Otsuka America Pharmaceutical, Inc.$390
- plus $5K from 44 others
What the payments were for
- Food & beverage$7,52697%
- Education$1993%
- Entertainment$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,738 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $111,182 |
| EliquisApixaban | 43 | $42,381 |
| RybelsusSemaglutide | 24 | $37,360 |
| FarxigaDapagliflozin Propanediol | 27 | $33,633 |
| JardianceEmpagliflozin | 32 | $32,951 |
| XareltoRivaroxaban | 25 | $29,621 |
| JanuviaSitagliptin Phosphate | 51 | $28,513 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $20,019 |
| MounjaroTirzepatide | 13 | $16,488 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $15,690 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $15,561 |
| LinzessLinaclotide | 17 | $14,236 |
| MyrbetriqMirabegron | 17 | $13,867 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $12,324 |
| Repatha SureclickEvolocumab | 13 | $11,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $551 | $148,54296 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $108 | $67,02199 claims |
| PfizerEliquis | $594 | $42,38143 claims |
| AstraZenecaFarxiga | $388 | $33,63327 claims |
| Boehringer IngelheimJardiance | $163 | $32,95132 claims |
| Johnson & JohnsonXarelto | $158 | $29,62125 claims |
| AbbVieLinzess, Synthroid | $553 | $17,56752 claims |
| Lilly USA, LLCMounjaro | $333 | $16,48813 claims |
| Astellas Pharma US IncMyrbetriq | $500 | $13,86717 claims |
| Esperion Therapeutics, Inc.Nexlizet | $319 | $10,82714 claims |
| GSKTrelegy Ellipta | $140 | $8,04012 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $31 | $2,718267 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Macon
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.